Colorectal cancer (CRC) is one of the most common malignancies both in men and women. 1 In recent years, CRC has a rising mortality rate mainly due to the liver metastases. 
chemotherapies based on 5-fluorouracil (5-FU) and irinotecan, have traditionally been treated as first-line regimens for metastatic CRC (mCRC). 4, 5 However, the prognosis of mCRC patients remains extremely poor due to the chemoresistance. 6 Nowadays, combination chemotherapy with agents which inhibit key cellular signaling pathways becoming a potential strategy to improve mCRC therapy. 7, 8 Notch pathway is a conserved signalling pathway which contributes to cell proliferation, epithelial-mesenchymal transition (EMT) and chemoresistance. 9, 10 Accumulating evidences indicated that Notch signalling pathway is dysregulated in nonsmall cell lung cancer (NSCLC), breast cancer and CRC. [11] [12] [13] Our previous study demonstrated that NSCLC cells acquire chemoresistance by activating Notch pathway.
14 Notch pathway is activated when ligands bind to related transmembrane receptors and cleaved by ADAM17 and a γ-secretase complex at S2 and S3 sites, then the cytoplasmic portion known as the Notch intracellular domain (NICD) was released. 9,15 ADAM17, also known as TNF-α converting enzyme (TACE), is responsible for S2 site cleavage and was important to disclose the S3 site in Notch pathway. 16 Chemotherapy, using in clinic for first-line, acutely induces the expression of ADAM17 17 and results in chemoresistance.
However, there is a small number of ADAM17 inhibitors reach to clinical trials for malignant tumour patients. 18 Thus, it is still a tremendous need for a novel inhibitor of ADAM17 to improve anti-tumour effects of chemotherapy or overcome cellular drug resistance in mCRC patients.
The early step of metastasis induced by activating Notch receptors in CRC was EMT. 19, 20 EMT is a highly coordinated process, in which epithelial cells acquired properties of mesenchymal cells. 11 Cancer cells, which undergone EMT involved in migration, invasion, chemoresistance 21 and linked to poor survival of cancer patients. 22 Down-regulated Notch pathway could reverse these effects and induce drug sensitivity. 23 We have found that terfenadine sensitized chemoresistant NSCLC cells to epirubicin by inhibiting Notch and EMT pathways. 14 RUI WANG et al reported that TAPI-2, an inhibitor of ADAM17, regulated cancer stem cells phenotype and chemosensitivity (5-FU) of CRC cells through Notch1
signaling. 24 In this study, we performed a virtual screening based on a pharmacophore model of ADAM17 which arranged atoms or groups of atoms in a molecule that determined its bioactivity against SPECS database. 25 Biological activity assays demonstrated that ZLDI-
methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione, was the most potential compound against 6 cancer cell lines especially in CRC. It has been reported that ZLDI-8 inhibited lymphoid-specific tyrosine phosphatase which predominantly expressed in immune cells for autoimmune diseases. 26 Whereas, its anti-tumour and underlying molecular mechanisms have not been clarified. In this study, we mainly explored the potential mechanism of antiproliferation and chemosensitization effect of ZLDI-8 in vitro and in vivo.
| MATERIAL S AND ME THODS

| Computational methods
All computational experiments were conducted on Dell PowerEdge R900 workstation under Redhat 6.4 platform.
| Reagents and antibodies
The selected compounds (ZLDI-1-14) were purchased from SPECS database, and the purity was more than 95%. ZLDI-8 was dissolved in dimethylsulphoxide (DMSO) and stored in −20°C. RPMI 1640 and DMEM were obtained from Hyclone (Logan, UT, USA). Antibodies for Notch1, 2, 3, E-cadherin, Vimentin, Hes1, Twist1, Survivin were purchased from CST (Beverly, MA). Antibodies against ADAM17 and Notch4 were purchased from Abcam (Cambridge, UK). β-actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The secondary antibodies were purchased from ZSGB-BIO (Beijing, China).
| Cell cultures
The non-small cell lung cancer (A549), human breast adenocarcinoma and RPMI-1640 (SW480) medium with 10% foetal bovine serum (FBS) and incubated in a humidified atmosphere containing 5% CO 2 at 37°C.
| Cell viability assay
Cancer cells were seeded in 96-well plates and then treated with ZLDI-8 
| ADAM17 enzymatic assay
The ADAM17 enzymatic assay was measured by ADAM17 Activity Assay Kit following the manufacturer's protocol. The human purified ADAM17 protein was treated with ZLDI-8 at different concentrations in a black 384-well plate, and the fluorescence intensity was measured by an automatic microplate reader.
| Colony formation assay
LoVo and SW480 cells were seeded in a 6-well plate with a density of 1 × 10 3 cells/well and treated with ZLDI-8 (3.13 μM), 5-FU (2 μM), irinotecan (8 μM) alone or combination. After 7 days, the colonies were stained with crystal violet and quantified by glacial acetic acid using the microplate reader (Elx 800 Bio-Tek, USA).
| Wound healing scratch assay
LoVo cells (7 × 10 5 /mL) was seeded in 6-well plates until they reached 90% confluence and formed a monolayer. A volume of 100 μL pipette tip was used to create scratch wounds and the cells were washed with phosphate-buffered saline (PBS). The migration of cells was observed after treating with ZLDI-8, 5-FU/irinotecan alone or combination.
Image J software was used to measure the wound area at 0 h and 72 h. Experiments were repeated at least 3 times.
| Cell invasion assay
The invasion ability of LoVo cells was assessed using 24-well tran- 
| Immunofluorescence images
LoVo cells were seeded into 24-well plates and treated with ZLDI- 
| Western blot analysis
Cells and tumour tissues were homogenized in RIPA buffer including protease inhibitor. The BCA Protein Assay Kit was used to determine the protein concentration of extracts. The total protein was separated by SDS-PAGE and electrophoretically transferred onto PVDF membranes. Membranes were immunoblotted using specific primary antibodies overnight and incubated with HRP-conjugated secondary antibodies. The immunoreactive bands were visualized by ECL detection kit.
| Animal experiments
All 5-week-old male BALB/cA-nu mice were purchased from Beijing
Vital River Laboratory Animal Technology in accordance with 
| Statistical analysis
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. One-way analysis of variance (ANOVA) was used to analyse the significance between the groups. All data are expressed as means values ± SEM. P < .05 indicated significance.
| Other methods
Please see "Supplementary materials and methods" in Data S1.
| RE SULTS
| Pharmacophore-based virtual screen to identify a potential ADAM17 inhibitor
Receptor-Ligand Pharmacophore results showed that the first pharmacophore (FigureS1A) was the most relevant to the Crystal structure of TACE-IK682 complex. 27 However, considering the restriction on screening, the secondary features H4 and H5 were deleted manually. Table S1 showed that eighteen co-crystallized ligands of ADAM17 27-40 could be identified by fitvalues with little change of AbsoluteEnergy and predicted by XSCORE mostly.
Therefore, an ideal pharmacophore model (pharmacophore a) was confirmed (Figures 1A and S1B), which including 1 hydrogen bond acceptor (A) mapped on the carbonyl group of the pyrrolidine, 2 hydrogen bond donors (D1 and D2) matched with hydroxamate moiety and 3 hydrophobic-aliphatic groups (H1, H2 and H3) mapped on the phenyl group and quinolinyl group of IK682. Pharmacophore a was used as a 3D structural query for retrieving SPECS database which was prepared previously. 41 As a result, fourteen compounds were selected based on their scaffolds and visual observations ( Figure S2 ).
Six human cancer cell lines including A549, HepG2, LoVo, KB, Hela and MCF-7 were used to estimate the anti-proliferative effect of fourteen compounds by MTT assay. Table 1 showed that ZLDI-8
inhibited the proliferation of 6 cancer cell lines especially in CRC (IC 50 value was 9.65 ± 3.3 μM at 24 h). In contrast, other compounds showed no significant effect on 6 human cancer cell lines (data not shown).
3D mapping and the molecular docking showed that ZLDI-8 interacts with most pharmacophore features and key amino acids of ADAM17 which including Leu348, Glu406, His405, Ala439, Leu401
and Leu402 ( Figure 1B and S1C). Consistent with the results of pharmacophore and docking, enzymatic activity assays showed that ZLDI-8 inhibited ADAM17 and the IC 50 value was approximately 72 μM (shown in Figure S1D ). Furthermore, we investigated the effect of ZLDI-8 on the ADAM17 protein level using western blot assay. Figure 1C ,D showed that the protein levels of ADAM17 were decreased both in SW480 and LoVo cells. values were calculated according to the equation as described by Kern et al. 42 Table S2A showed that the combination of ZLDI-8 with
| ZLDI-8 inhibited the effect of Notch pathway
5-FU exhibited synergistic anti-proliferation effects in LoVo and
SW480 cells (CI > 1.0). However, the combination of ZLDI-8 with
irinotecan only has synergistic effect in LoVo cells (Table S2B) .
To further investigate the synergistic anti-proliferation effect of ZLDI-8 with 5-FU or irinotecan, colony formation was performed. 
| ZLDI-8 sensitized CRC cells to 5-FU or irinotecan through Notch signalling pathway
Colorectal cancer cells respond to chemotherapy by increasing ADAM-17 activity, which further resulted in resistance.
17
Pharmacologic inhibition of ADAM17 in conjunction with
chemotherapy may enhance response rates of CRC patients. Figure 4A ,C,D showed that 5-FU or irinotecan increased the
F I G U R E 2 ZLDI-8 attenuates colorectal cancer cells growth in vitro though Notch pathway. A, The growth inhibition was evaluated after the cells were treated with the indicated concentrations of ZLDI-8 in SW480 and LoVo cells for 48 h. B, ZLDI-8 decreased the viability of SW480 and LoVo cells in a time-dependent manner. C, Cell proliferation was assessed by colony formation assay in SW480 and LoVo cells. D, Bar graphs showed the quantitative results of clonogenicity viability. E, Western blot assay was used to assess the expression of
Notch pathway members (N1-4ICD and Hes1) and anti-apoptosis protein survivin. β-actin was used as a loading control. *P < .05. **P < .01, ***P < .001 vs control 
TA B L E 2 ZLDI-8 enhanced the sensitivity of LoVo cells to FU or irinotecan
| ZLDI-8 sensitized CRC cells to 5-FU or irinotecan by reversing EMT process
EMT is a major mechanism that involves in migration, invasion and chemoresistance. 21 The wound healing scratch assay showed that ZLDI-8, 5-FU or irinotecan slightly inhibited the migration ability of 
| ZLDI-8 enhanced in vivo anti-tumour effect of 5-FU on CRC cells
We next tested the combined therapeutic effect of ZLDI-8 with Figure 7E ). At the same time, the protein levels of ADAM17, N1ICD and Hes1 were increased in 5-FU treatment, and this effect was reversed by combining with ZLDI-8 ( Figure 7E ). In addition, the expression of N2ICD and N4ICD was remarkably decreased, while the N3ICD has no significant change in the combination group ( Figure 7E ). Collectively, all results suggested that ZLDI-8 might enhance the anti-proliferation and anti-metastases effects of 5-FU by inhibiting Notch signalling pathway and EMT process.
| D ISCUSS I ON
In mCRC, chemotherapy is the primary option to reduce tumour recurrence and prolong survival. 43 However, the resistance of CRC cells to chemotherapy is the major obstacle for clinical application.
Though targeted therapies were approved in recent years, the resistance was also an emergent problem. 43 A novel inhibitor of potent pathways in conjunction with chemotherapy may be a potential approach for treatment with chemoresistance. In this study, we found a novel ADAM17 inhibitor ZLDI-8 which cell-specifically inhibited the proliferation of CRC and sensitized CRC to 5-FU by reversing Notch and EMT pathway in vitro and in vivo.
ADAM17 was an indispensable regulator of almost all cellular events in ovarian cancer, non-small cell lung cancer, breast cancer or CRC. [44] [45] [46] [47] [48] It involved in a series of substrates, including cytokines, growth factors, TNF-α and Epidermal Growth Factor Receptor (EGFR), especially in Notch pathway which contributed to chemoresistance. 44, 49 Inhibition of ADAM17 is a potent approach to target the activation of Notch signalling and decrease tumourigenicity and metastasis in CRC. 6 Therefore, inhibition of ADAM17 and synergistic interaction with existing chemotherapy may improve the outcomes of therapy for CRC patients. 17, 50 Computational methods are important tools to design and screen activity compounds in recent years. Moreover, relationships among compounds, scaffolds and biological activities are initiating to be globally explored, beyond individual applications. 25 In this study, we generated a pharmacophore model based on ADAM17 (PDB: 2FV5)
validated by Fitvalues, AbsoluteEnergy and XSCORE, and gained protein.
In CRC, accumulating evidences indicated that Notch signalling plays an oncogenic role. 51 But, not all signalling components related to the development of CRC. 52 In this study, we demonstrated that the expression of N1ICD, N2ICD and N4ICD was down-regulated by ZLDI-8. However, there was no significant difference in the protein for metastatic malignancies as a single agent or combination with chemotherapeutical drugs were studied. 54 It is reported that GSI34 or parthenolide sensitized CRC cells to chemotherapy and synergistic with 5-FU or irinotecan. 53, 55 In this study, we demonstrated that ZLDI-8 synergistically enhanced the anti-proliferation effect when combined with 5-FU or irinotecan. Meanwhile, ZLDI-8 sensitized both 5-FU and irinotecan in LoVo cells more than SW480.
It has been shown that Notch pathway is implicated in EMT process, in which epithelial cells obtain a mesenchymal phenotype, ultimately leading to migration and invasion. 13, 23 Significantly 
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